H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis

Company Overview

H. Lundbeck A/S is a Denmark-based global pharmaceutical company specializing in the research, development and commercialization of treatments for psychiatric and neurological disorders. With a focus on central nervous system (CNS) conditions, Lundbeck’s product portfolio includes antidepressants, antipsychotics, Alzheimer’s disease therapies and treatments for epilepsy, migraine and Parkinson’s disease. The company emphasizes both established small-molecule drugs and innovative approaches to meet unmet medical needs in brain health.

Among Lundbeck’s key marketed products are escitalopram (sold under the brand name Cipralex or Lexapro in various markets), the atypical antipsychotic Abilify Maintena, and vortioxetine (Trintellix/Brintellix), an antidepressant with multimodal activity. In addition to its on-market therapies, the company maintains a robust R&D pipeline with clinical-stage candidates targeting neurodegenerative diseases, mood disorders and rare neurological conditions. Lundbeck collaborates with academic institutions, biotech partners and other pharmaceutical companies to advance its early-stage discovery programs.

Founded in 1915 by Hans Lundbeck, the company has grown from a family-owned enterprise into a multinational organization with headquarters in Copenhagen, Denmark. It conducts research and manufacturing operations in Europe, North America and Asia, and markets its products in more than 50 countries worldwide. Lundbeck’s global footprint is supported by regional affiliates and partnerships that help ensure access to its CNS therapies for patients and healthcare providers across key markets.

Lundbeck’s corporate strategy centers on deepening its expertise in neuroscience, strengthening its commercial capabilities and pursuing acquisitions and alliances that complement its core CNS focus. By combining scientific innovation with a patient-centric approach, the company aims to deliver sustainable growth while addressing the complex challenges of brain health on a global scale.

Key Stats

• Today's Range: $22.00 to $24.00
• 50-Day Range: $22.00 to $22.00
• 52-Week Range: $10.00 to $31.55
• Volume: 7,500 shs
• Average Volume: 1,758 shs
• Market Capitalization: $21.91 billion
• P/E Ratio: 25.00
• Dividend Yield: 0.91%
• Price Target: N/A
• Consensus Rating: N/A

HLUYY Stock Analysis - Frequently Asked Questions

How have HLUYY shares performed this year?

H. Lundbeck A/S's stock was trading at $22.00 at the start of the year. Since then, HLUYY shares have increased by 0.0% and is now trading at $22.00.

How were H. Lundbeck A/S's earnings last quarter?

H. Lundbeck A/S (OTCMKTS:HLUYY) issued its quarterly earnings results on Wednesday, November, 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.16. The business had revenue of $547.05 million for the quarter, compared to analysts' expectations of $514.82 million. H. Lundbeck A/S had a trailing twelve-month return on equity of 13.74% and a net margin of 6.74%.

Does H. Lundbeck A/S have any subsidiaries?

H. Lundbeck A/S subsidiaries include these companies: Alder BioPharmaceuticals, and Prexton Therapeutics.

How do I buy shares of H. Lundbeck A/S?

Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/04/2015
• Today: 8/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private Households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HLUYY
• CIK: N/A
• Web: www.lundbeck.com
• Phone: (453) 630-1311
• Fax: 45-3630-1940
• Employees: 5,348
• Year Founded: 1915

Profitability

• EPS (Trailing Twelve Months): $0.88
• Trailing P/E Ratio: 25.00
• Forward P/E Ratio: 10.48
• P/E Growth: N/A
• Net Income: $209.69 million
• Net Margins: 6.74%
• Pretax Margin: 7.83%
• Return on Equity: 13.74%
• Return on Assets: 7.16%

Debt

• Debt-to-Equity Ratio: 0.32
• Current Ratio: 1.15
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $2.59 billion
• Price / Sales: 8.45
• Cash Flow: $3.36 per share
• Price / Cash Flow: 6.54
• Book Value: $14.60 per share
• Price / Book: 1.51

Miscellaneous

• Outstanding Shares: 995,741,000
• Free Float: N/A
• Market Cap: $21.91 billion
• Optionable: Not Optionable
• Beta: 0.68